Joanne Kotz (Jnana)
Roche partners on a slate of Jnana's immunology, neurology targets, rewarding its faith in the SLC transporter class
When Jnana Therapeutics launched in late 2017 with $50 million in the bank, the biotech billed itself as the first to focus solely and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
